Español (soon!) - August 20, 2008
CMEonHIV.com is dedicated to providing online CME presentations (slides with voiceover) on HIV/AIDS for healthcare professionals given by local and international experts to keep you up-to-date on the ongoing developments in the field.
  Biography  

Prof. Mark Wainberg

Current Position
Professor and Director,
McGill University AIDS Centre, Jewish General Hospital
Montreal, Quebec


Primary Areas of Interest
Viral Drug Resistance Fitness
Anti-Viral Drug Development

Post-Graduate Training
Columbia University, New York

Memberships
International AIDS Society
Canadian Association for HIV Research
American Society for Microbiology

Recent Publications
Brenner BG, Routy JP, Petrella M, Moisi D, Oliveira M, Detorio M, Spira B, Essabag V, Conway B, Lalonde R, Sekaly RP, Wainberg MA. Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection. J Virol 2002;76:1753-1761.
Gotte M, Arion D, Parniak MA and Wainberg MA. The M184V mutation in the reverse transcriptase of the human immunodeficiency virus type 1 impairs rescue of chain-terminated DNA synthesis. J Virol 2000;74:3579-3585.
Kameoka M, Rong L, Gotte M, Liang C, Russell RS and Wainberg MA. A role for the Tat Protein of HIV-1 in suppression of viral reverse transcriptase activity during late stages of viral replication. J Virol 2001;75:2675-2683.

Honours/Awards
Officer of the Order of Canada
Fellow of Royal Society of Canada
Past-President, International AIDS Society
 
  List of presentations from this healthcare provider available on CMEonHIV :

Benefits of Maintaining the M184V Mutation in Clinical Therapy of HIV...
Bases for the use of 3TC in clinical practice
Optimizing antiretroviral therapy-resistance and sequencing
Le «fitness» viral modifie-t-il la résistance aux drogues dans le...
Viral Fitness
Situation globale sur le sida : Que pouvons nous faire contre le VIH/SIDA?
Les principes de résistance
Differences Among HIV Subtypes in Regard to Drug Resistance
L'importance de maintenir la mutation M184V
Update on Resistance Profiles of Nucleoside Analogs
Préservation des options thérapeutiques pour éviter la résistance croisée...
Introduction: Initiating and Managing Treatment with Abacavir - A...
Introduction : Amorce et planification d'un traitement par l'abacavir - un...
  Login

  Please log in and get access to thousands of resources about HIV disease and its treatment.
 
Already a member?
  Username :
  Password :
   
 
  Lost your password?


  Search our database
  Find the information that you are looking for in over +3000 resources.
 
web cmeonhiv.com



CMEonHIV is owned by E-MedHosting.com.

Copyright @ 2002-2008 E-MedHosting.com. All rights reserved.  Disclaimer  |  Sponsor Disclaimer


USER ACKNOWLEDGES AND AGREES THAT ALL DECISIONS MADE WITH THE ASSISTANCE OR USE OF THE SOFTWARE AND/OR THE WEBSITE AND/OR
BASED ON CONTENT FOUND HEREIN WILL BE EXCLUSIVELY THE RESPONSIBILITY OF THE USER.
C-Reactive Protein (CRP)